Search

Your search keyword '"de Vita F"' showing total 603 results
Start Over Author "de Vita F" Language english
603 results on '"de Vita F"'

1. Critical appraisal of the use of regorafenib in the management of colorectal cancer

Author

Festino L, Fabozzi A, Manzo A, Gambardella V, Martinelli E, Troiani T, De Vita F, Orditura M, Ciardiello F, and Morgillo F

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Lucia Festino*, Alessio Fabozzi*, Anna Manzo, Valentina Gambardella, Erika Martinelli, Teresa Troiani, Ferdinando De Vita, Michele Orditura, Fortunato Ciardiello, Floriana Morgillo Division of Medical Oncology, Department of clinical and experimental medicine and surgery "F. Magrassi e A. Lanzara", Second University of Naples, Napoli, Italy*These authors contributed equally to this work Abstract: The lack of valid clinical management options for patients affected by metastatic colorectal cancer, which has progressed after all approved standard treatments, has lead to research into new active molecules. Regorafenib is an oral small-molecule multi kinase inhibitor, binding to several intracellular kinases, with powerful inhibitory activity against vascular endothelial growth factor receptors (VEGFR-1,VEGFR-2, and VEGFR-3), platelet-derived growth factor receptor, fibroblast growth factor receptor 1, Raf, TIE-2, and the kinases KIT, RET, and BRAF. The antitumor activity of regorafenib has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in several cancer models, particularly colorectal cancer and gastrointestinal stromal tumors. The most frequent adverse events of grade 3 or higher related to regorafenib were hand-foot skin reaction, fatigue, diarrhea, hypertension, and rash or desquamation. Only a few Phase I–II trials, and most recently a Phase III trial in pretreated colorectal cancer, have been carried out to date. Several ongoing trials are testing the efficacy of regorafenib in combination with chemotherapy. At this point in time, regorafenib is the first small-molecule tyrosine kinase inhibitor to gain approval by the US Food and Drug Administration for pretreated metastatic colorectal cancer patients. Keywords: colorectal cancer, angiogenesis, regorafenib

Published
2013

2. Does Veritas® play a role in breast reconstruction? a case report

Author

De Vita F, Anniboletti T, and Borgognone A

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Alessandro Borgognone, Tommaso Anniboletti, Francesco De VitaDepartment of Plastic and Reconstructive Surgery, CTO Hospital, Rome, ItalyAbstract: To reduce operative times and surgical complications in implant-based breast reconstruction, many authors advocate the use of exogenous material (modified xenograft) to support tissue regeneration. In this article, a case is presented in which a bovine collagen patch (Veritas® Collagen Matrix; Synovis Surgical Innovations, St Paul, MN) was used in the immediate breast reconstruction with an implant. The good results obtained in this case confirm Veritas® as a viable alternative to AlloDerm® Regenerative Tissue Matrix (LifeCell Corporation, Branchburg, NJ) and further support its ability to sustain and stimulate recovery of the surrounding tissues.Keywords: Veritas®, implant-based, breast reconstruction, bovine collagen, patch

Published
2011

3. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial

Author

Ciardiello, Davide, Bielo, Luca Boscolo, Napolitano, Stefania, Martinelli, Erika, Troiani, Teresa, Nicastro, Antonella, Latiano, Tiziana Pia, Parente, Paola, Maiello, Evaristo, Avallone, Antonio, Normanno, Nicola, Pisconti, Salvatore, Nisi, Claudia, Bordonaro, Roberto, Russo, Alessia Erika, Tamburrini, Emiliano, Toma, Ilaria, Lotesoriere, Claudio, Vallarelli, Simona, Zampino, Maria Giulia, Fazio, Nicola, Curigliano, Giuseppe, Ciardiello, Fortunato, Martini, Giulia, Lonardi, Sara, Cremolini, Chiara, Garufi, Carlo, Tagliaferri, Pierosandro, Tortora, Giampaolo, Pietrantonio, Filippo, Febbraro, Antonio, Rosati, Gerardo, Leo, Silvana, Brunetti, Oronzo, Berardi, Rosanna, Cinieri, Saverio, Scartozzi, Mario, Zaniboni, Alberto, Paoletti, Giancarlo, Ciardiello, D., Boscolo Bielo, L., Napolitano, S., Martinelli, E., Troiani, T., Nicastro, A., Latiano, T.P., Parente, P., Maiello, E., Avallone, A., Normanno, N., Pisconti, S., Nisi, C., Bordonaro, R., Russo, A.E., Tamburini, E., Toma, I., Lotesoriere, C., Vallarelli, S., Zampino, M.G., Fazio, N., Curigliano, G., De Vita, F., Ciardiello, F., and Martini, G.

Published
2024
Full Text
View/download PDF

5. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

Author

Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M.G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., Rapisardi, S., Bordonaro, R., Zichi, C., De Vita, F., Di Maio, M., Parisi, A., Giampieri, R., Berardi, R., Lavacchi, D., Antonuzzo, L., Tamburini, E., Maiorano, B.A., Parrella, P., Latiano, T.P., Normanno, N., De Stefano, A., Avallone, A., Martini, G., Napolitano, S., Troiani, T., Martinelli, E., Ciardiello, F., and Maiello, E.

Published
2022
Full Text
View/download PDF

6. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Author

Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M.C., Rodriquenz, M.G., Centonze, F., Rapposelli, I.G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L.G., Orsi, G., Valente, M.M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

9. Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs

Author

Orditura, M., Della Corte, C.M., Diana, A., Ciaramella, V., Franzese, E., Famiglietti, V., Panarese, I., Franco, R., Grimaldi, A., Lombardi, A., Caraglia, M., Santoriello, A., Procaccini, E., Lieto, E., Maiello, E., De Vita, F., Ciardiello, F., and Morgillo, F.

Published
2018
Full Text
View/download PDF

10. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Author

Iaffaioli, Vincenzo, Nasti, Guglielmo, Botti, Gerardo, Tatangelo, F., Chicchinelli, Nicoletta, Montrone, Mirko, Sebastio, Annamaria, Guarino, Tiziana, Simone, Gianni, Graziano, Paolo, Chiarazzo, Cinzia, Di Maggio, Gabriele, Longhitano, Laura, Manusia, Mario, Cartenì, Giacomo, Nappi, Oscar, Micheli, Pietro, Leo, Luigi, Rossi, Sabrina, Cassano, Alessandra, Tommaselli, Eugenio, Giordano, Guido, Sponziello, Francesco, Marino, Antonella, Rinaldi, Antonio, Romito, Sante, Muda, Andrea Onetti, Lorusso, Vito, Leo, Silvana, Barni, Sandro, Grimaldi, Giuseppe, Aieta, Michele, Ciardiello, F., Normanno, N., Martinelli, E., Troiani, T., Pisconti, S., Cardone, C., Nappi, A., Bordonaro, A.R., Rachiglio, M., Lambiase, M., Latiano, T.P., Modoni, G., Cordio, S., Giuliani, F., Biglietto, M., Montesarchio, V., Barone, C., Tonini, G., Cinieri, S., Febbraro, A., Rizzi, D., De Vita, F., Orditura, M., Colucci, G., and Maiello, E.

Published
2016
Full Text
View/download PDF

11. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

Author

Martinelli, E., Cardone, C., Troiani, T., Normanno, N., Pisconti, S., Sforza, V., Bordonaro, A.R., Rachiglio, A.M., Lambiase, M., Latiano, T.P., Modoni, G., Cordio, S., Giuliani, F., Biglietto, M., Montesarchio, V., Barone, C., Tonini, G., Cinieri, S., Febbraro, A., Rizzi, D., De Vita, F., Orditura, M., Colucci, G., Maiello, E., Ciardiello, F., Iaffaioli, Vincenzo, Nasti, Guglielmo, Nappi, Anna, Botti, Gerardo, Tatangelo, F., Chicchinelli, Nicoletta, Montrone, Mirko, Sebastio, Annamaria, Guarino, Tiziana, Simone, Gianni, Graziano, Paolo, Chiarazzo, Cinzia, Maggio, GabrieleDi, Longhitano, Laura, Manusia, Mario, Cartenì, Giacomo, Nappi, Oscar, Micheli, Pietro, Leo, Luigi, Rossi, Sabrina, Cassano, Alessandra, Tommaselli, Eugenio, Giordano, Guido, Sponziello, Francesco, Marino, Antonella, Rinaldi, Antonio, Romito, Sante, Muda, Andrea Onetti, Lorusso, Vito, Leo, Silvana, Barni, Sandro, Grimaldi, Giuseppe, and Aieta, Michele

Published
2016
Full Text
View/download PDF

12. Attributable mortality of carbapenem-resistant Klebsiella pneumoniae infections in a prospective matched cohort study in Italy, 2012–2013

Author

Tura, G.A., Rossi, A., Pedna, M.F., Minghetti, M., Zoli, M., Chiesa, M., Carminati, A., Ceccarelli, P., Costa, E., Tejada, M., Castaldo, F., Carpinelli, L., Nelli, M., Sansone, P., Chiossone, T., Cenderello, N., Fabbri, P., Crisalli, M.P., Poli, A., Fornai, E., Niccolini, F., Pecile, P., Magistri, L., Mantengoli, E., Bianco, I., Gambi, A., Pompeo, M.A., Silverj, F., di Girolamo, A., de Vita, F., Argentieri, A., Gatti, S., Milano, F., Franchino, M., Siciliano, C., Dusi, P.A., Dotta, M., Assensi, M., Montoro, S., Farina, C., Cosentino, M., Vailati, F., Hoxha, A., Kärki, T., Giambi, C., Montano, C., Sisto, A., Bella, A., and D'Ancona, F.

Published
2016
Full Text
View/download PDF

15. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

Author

Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A.M., Montesarchio, V., Tonini, G., Rizzi, D., Cinieri, S., Bordonaro, R., Febbraro, A., De Vita, F., Orditura, M., Fenizia, F., Lambiase, M., Rinaldi, A., Tatangelo, F., Botti, G., and Colucci, G.

Published
2014
Full Text
View/download PDF

18. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

Author

Ciardiello, D, Chiarazzo, C, Famiglietti, V, Damato, A, Pinto, C, Zampino, M G, Castellano, G, Gervaso, L, Zaniboni, A, Oneda, E, Rapisardi, S, Bordonaro, R, Zichi, C, De Vita, F, Di Maio, M, Parisi, A, Giampieri, R, Berardi, R, Lavacchi, D, Antonuzzo, L, Tamburini, E, Maiorano, B A, Parrella, P, Latiano, T P, Normanno, N, De Stefano, A, Avallone, A, Martini, G, Napolitano, S, Troiani, T, Martinelli, E, Ciardiello, F, Maiello, E, Ciardiello, D, Chiarazzo, C, Famiglietti, V, Damato, A, Pinto, C, Zampino, M G, Castellano, G, Gervaso, L, Zaniboni, A, Oneda, E, Rapisardi, S, Bordonaro, R, Zichi, C, De Vita, F, Di Maio, M, Parisi, A, Giampieri, R, Berardi, R, Lavacchi, D, Antonuzzo, L, Tamburini, E, Maiorano, B A, Parrella, P, Latiano, T P, Normanno, N, De Stefano, A, Avallone, A, Martini, G, Napolitano, S, Troiani, T, Martinelli, E, Ciardiello, F, and Maiello, E

Subjects
KRASG12C mutation, Cancer Research, real-world data, Irinotecan, chemotherapy, first line treatment, Oxaliplatin, Treatment Outcome, Oncology, mCRC, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Fluorouracil, Colorectal Neoplasms, Retrospective Studies
Abstract

Background: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patients with KRASG12C mCRC treated in 12 Italian oncology units. Patients and methods: Patients with unresectable mCRC harboring KRASG12C mutation receiving a first-line chemotherapy doublet or triplet between 2011 and 2021 were included in the study. Evaluation of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) analysis was carried out. Results: A total of 256/6952 (3.7%) patients with mCRC displayed KRASG12C mutation; of these, 111 met the inclusion criteria. The ORR of first-line therapy was 38.7% (43/111). Median PFS (mPFS) was 9 months [95% confidence interval (CI) 7.5-10.5 months]. After progression, only 62% and 36% of the patients are fit to receive second or third lines of treatment, with limited clinical benefit. Median OS (mOS) was 21 months (95% CI 17.4-24.6 months). In patients receiving first-line triplet chemotherapy, ORR was 56.3% (9/16), mPFS was 13 months (95% CI 10.3-15.7 months) and mOS was 32 months (95% CI 7.7-56.3 months). For irinotecan-based doublets, ORR was 34.5 (10/29), mPFS was 9 months (95% CI 6.4-11.6 months) and mOS was 22 months (95% CI 16.0-28.0 months). With oxaliplatin-based doublets ORR was 36.4% (24/62), mPFS was 7 months (95% CI 4.6-9.4 months) and mOS was 18 months (95% CI, 13.6-22.4 months). Conclusion: Patients with KRASG12C-mutant mCRC had a disappointing response to standard treatments. Within the limitations of a retrospective study, these results suggest that first-line chemotherapy intensification with FOLFOXIRI is a valid option in fit patients.

Published
2022

21. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Author

Ciardiello, F., Normanno, N., Martinelli, E., Troiani, T., Pisconti, S., Cardone, C., Nappi, A., Bordonaro, A. R., Rachiglio, M., Lambiase, M., Latiano, T. P., Modoni, G., Cordio, S., Giuliani, F., Biglietto, M., Montesarchio, V., Barone, C., Tonini, G., Cinieri, S., Febbraro, A., Rizzi, D., De Vita, F., Orditura, M., Colucci, G., Maiello, E., Iaffaioli, Vincenzo, Nasti, Guglielmo, Botti, Gerardo, Tatangelo, F., Chicchinelli, Nicoletta, Montrone, Mirko, Sebastio, Annamaria, Guarino, Tiziana, Simone, Gianni, Graziano, Paolo, Chiarazzo, Cinzia, Di Maggio, Gabriele, Longhitano, Laura, Manusia, Mario, Cartenì, Giacomo, Nappi, Oscar, Micheli, Pietro, Leo, Luigi, Rossi, Sabrina, Cassano, Alessandra, Tommaselli, Eugenio, Giordano, Guido, Sponziello, Francesco, Marino, Antonella, Rinaldi, Antonio, Romito, Sante, Muda, Andrea Onetti, Lorusso, Vito, Leo, Silvana, Barni, Sandro, Grimaldi, Giuseppe, and Aieta, Michele

Published
2016
Full Text
View/download PDF

22. Correction to: Discrepancy of p16 immunohistochemical expression and HPV RNA in penile cancer. A multiplex in situ hybridization/immunohistochemistry approach study (Infectious Agents and Cancer, (2021), 16, 1, (22), 10.1186/s13027-021-00361-8)

Author

Marino F. Z., Sabetta R., Pagliuca F., Brunelli M., Aquino G., Perdona S., Botti G., Facchini G., Fiorentino F., Di Lauro G., De Sio M., De Vita F., Toni G., Reis R. B. D., Neder L., Franco R., Marino, F. Z., Sabetta, R., Pagliuca, F., Brunelli, M., Aquino, G., Perdona, S., Botti, G., Facchini, G., Fiorentino, F., Di Lauro, G., De Sio, M., De Vita, F., Toni, G., Reis, R. B. D., Neder, L., and Franco, R.

Abstract

Following publication of the original article [1], the authors identified an error in the author name of Federica Zito Marino. ● The incorrect author name is: Federico Zito Marino ● The correct author name is: Federica Zito Marino The author group has been updated above and the original article [1] has been corrected.

Published
2021

30. SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial

Author

Ciardiello, D., Napolitano, S., De Falco, V., Martini, G., Martinelli, E., Della Corte, C., Esposito, L., Famiglietti, V., Di Liello, A., Avallone, A., Cardone, C., De Stefano, A., Montesarchio, V., Zampino, M., Fazio, N., Del Tufo, S., Di Maio, M., De Vita, F., Altucci, L., Marrone, F., Ciardiello, F., and Troiani, T.

Published
2023
Full Text
View/download PDF

34. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial

Author

Comella, P., Massidda, B., Filippelli, G., Palmeri, S., Natale, D., Farris, A., De Vita, F., Buzzi, F., Tafuto, S., Maiorino, L., Mancarella, S., Leo, S., Lorusso, V., De Lucia, L., and Roselli, M.

Published
2005
Full Text
View/download PDF

48. Hymovis MO.RE. in the treatment of knee and ankle chondropathy in elite athletes: preliminary results of the CHAMPS (Cohort study about HYADD4-G Administration for Pain relief on Soccer players) prospective clinical study.

Author

PERTICARINI, L., BALDARI, A., BRUZZONE, M., COMBI, F., CUGAT, R., DE VITA, F., FRESCHI, M., GIAGNORIO, R., IGLESIAS, J. G., MORETTI, B., PASSELLI, A., SCORCU, M., VILLALON, J. M., and BENAZZO, F.

Abstract

OBJECTIVE: This study evaluated single intra-articular injections of Hymovis MO.RE., a hyaluronic acid hexadecyl derivative (HYADD4-G), to manage post-traumatic or degenerative knee or ankle chondropathy in professional soccer players. PATIENTS AND METHODS: Twenty-five players affected by knee (n = 12) or ankle (n = 13) chondropathy were prospectively enrolled and treated by two single Hymovis MO.RE. (32 mg/4 ml) injections at the beginning of the football season (V0, baseline) and at mid-season (V1, 19-20 weeks thereafter), and were followed-up until the end of the season (V2, after further 19-20 weeks). Knee cases were evaluated using the 2000 IKDC knee subjective examination form and the modified Lysholm scoring system. Ankle cases were evaluated using the American Orthopaedic Foot Ankle Society (AOFAS) ankle-hindfoot score. Patients were also evaluated using a VAS Likert scale and a four-category scale recording both the patient's and the doctor's assessment on joint mobility in degrees and overall treatment efficacy. Adverse events, patient withdrawals and local reaction to injections were also assessed. RESULTS: In knee patients, the 2000 IKDC subjective score improved from 46.8 ± 11.4 at V0 to 83.1 ± 12.5 at V2. Their modified Lysholm score improved from 58.8 ± 8.9 at V0 to 90.6 ± 8.3 at V2. In the ankle patients, the AOFAS score improved from 52.2 ± 5.6 at V0 to 96.4 ± 4.5 at V2. VAS Likert values and subjective evaluations improved at V1 and were maintained at V2. No side effects were recorded. CONCLUSIONS: A single Hymovis MO.RE. (32 mg/4 ml) intra-articular injection, repeated after 19-20 weeks, may be a viable option to improve symptoms and function in professional soccer players suffering from knee and ankle chondropathy. [ABSTRACT FROM AUTHOR]

Published
2021

50. Mitochondrial AKAP1 supports mTOR pathway and tumor growth

Author

Rinaldi L., Sepe M., Delle Donne R., Conte K., Arcella A., Borzacchiello D., Amente S., De Vita F., Porpora M., Garbi C., Oliva M. A., Procaccini C., Faicchia D., Matarese G., Zito Marino F., Rocco G., Pignatiello S., Franco R., Insabato L., Majello B., Feliciello A., ZITO MARINO, Federica, Rinaldi, L., Sepe, M., Delle Donne, R., Conte, K., Arcella, A., Borzacchiello, D., Amente, S., De Vita, F., Porpora, M., Garbi, C., Oliva, M. A., Procaccini, C., Faicchia, D., Matarese, G., Zito Marino, F., Rocco, G., Pignatiello, S., Franco, R., Insabato, L., Majello, B., Feliciello, A., ZITO MARINO, Federica, Rinaldi, Laura, Sepe, Maria, Delle Donne, Rossella, Conte, Kristel, Arcella, Antonietta, Borzacchiello, Domenica, Amente, Stefano, De Vita, Fernanda, Porpora, Monia, Garbi, Corrado, Oliva, Maria A, Procaccini, Claudio, Faicchia, Deriggio, Matarese, Giuseppe, Zito Marino, Federica, Rocco, Gaetano, Pignatiello, Sara, Franco, Renato, Insabato, Luigi, Majello, Barbara, and Feliciello, Antonio

Subjects
0301 basic medicine, Scaffold protein, Male, Cancer Research, Lung Neoplasms, Transcription, Genetic, A Kinase Anchor Proteins, Mitochondrion, mTORC2, RNA, Small Interfering, Nuclear Protein, Mitochondrial, AKAP1, mTOR, TOR Serine-Threonine Kinase, Brain Neoplasms, TOR Serine-Threonine Kinases, Nuclear Proteins, A Kinase Anchor Protein, 3. Good health, Cell biology, Mitochondria, Gene Expression Regulation, Neoplastic, Original Article, Survival Analysi, Signal transduction, Neuroglia, Protein Binding, Signal Transduction, Immunology, Mice, Nude, Biology, Brain Neoplasm, Proto-Oncogene Proteins c-myc, 03 medical and health sciences, Cellular and Molecular Neuroscience, Cell Line, Tumor, Animals, PI3K/AKT/mTOR pathway, Cell Proliferation, Epithelial Cell, Cell growth, Animal, RPTOR, Epithelial Cells, Cell Biology, Survival Analysis, Lung Neoplasm, 030104 developmental biology, Cancer research, Organelle biogenesis, Neoplasm Transplantation
Abstract

Mitochondria are the powerhouses of energy production and the sites where metabolic pathway and survival signals integrate and focus, promoting adaptive responses to hormone stimulation and nutrient availability. Increasing evidence suggests that mitochondrial bioenergetics, metabolism and signaling are linked to tumorigenesis. AKAP1 scaffolding protein integrates cAMP and src signaling on mitochondria, regulating organelle biogenesis, oxidative metabolism and cell survival. Here, we provide evidence that AKAP1 is a transcriptional target of Myc and supports the growth of cancer cells. We identify Sestrin2, a leucine sensor and inhibitor of the mammalian target of rapamycin (mTOR), as a novel component of the complex assembled by AKAP1 on mitochondria. Downregulation of AKAP1 impaired mTOR pathway and inhibited glioblastoma growth. Both effects were reversed by concomitant depletion of AKAP1 and sestrin2. High levels of AKAP1 were found in a wide variety of high-grade cancer tissues. In lung cancer, AKAP1 expression correlates with high levels of Myc, mTOR phosphorylation and reduced patient survival. Collectively, these data disclose a previously unrecognized role of AKAP1 in mTOR pathway regulation and cancer growth. AKAP1/mTOR signal integration on mitochondria may provide a new target for cancer therapy.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results